v3.26.1
SEGMENT INFORMATION
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
SEGMENT INFORMATION SEGMENT INFORMATION
Reportable Segments
The following is a brief description of the Company’s reportable segments:
•The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan® product line currently represent approximately 85% of the Salix segment revenues.
•The International segment consists of sales, with the exception of sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the U.S. of branded pharmaceutical products, branded generic pharmaceutical products and OTC products.
•The Solta Medical segment consists of global sales of Solta Medical aesthetic medical devices.
•The Diversified segment consists of sales in the U.S. of: (i) pharmaceutical products in the areas of neuroscience and certain other therapeutic classes, (ii) dermatology products, (iii) generic pharmaceutical products and (iv) dentistry products.
•The Bausch + Lomb segment consists of global sales of Bausch + Lomb Vision Care, Surgical and Pharmaceuticals products.
Resources are allocated and performance is assessed by the Company’s CEO, whom the Company has determined to be the Company’s Chief Operating Decision Maker (the “CODM”). The Company’s CODM evaluates the performance of its segments and allocates resources to them based on segment profit. Segment profit is based on operating income after the elimination of intercompany transactions. Certain costs, such as Amortization of intangible assets, Goodwill impairments, Restructuring, integration and separation costs and Other expense (income), net, are not included in the measure of segment profit, as management excludes these items in assessing segment financial performance.
The CODM uses segment profit in the annual budgeting and forecasting process. The CODM considers budget-to-actual variances on a monthly basis for segment profit when making decisions about allocating capital and personnel to the segments. The CODM uses segment profit in determining the compensation of certain employees. In assessing segment performance and managing operations, the CODM does not review segment assets.
Corporate includes the finance, treasury, certain research and development programs, tax and legal operations of the Company’s businesses and certain expenses, gains and losses related to the overall management of the Company, which are not allocated to the other business segments. Furthermore, a portion of share-based compensation is considered a corporate cost since the amount of such expense depends on company-wide performance rather than the operating performance of any single segment.
Segment Revenues and Profits
Segment revenues, profits and reconciliation of segment profit to consolidated Income (loss) before income taxes were as follows:
Three Months Ended June 30,
SalixInternationalSolta MedicalDiversifiedBausch + LombTotal
(in millions)202620252026202520262025202620252026202520262025
Revenues$758$627$305$278$176$128$219$219$1,394$1,278$2,852$2,530
Less:
Cost of goods sold (a)
403912011736363033527523
Cost of other revenues——1914—————2
Selling, general and administrative100112676340324343476470
Research and development13219696445635
Segment profit$605$455$90$78$91$54$142$139$335$248$1,263$974
Corporate(263)(261)
Amortization of intangible assets(225)(256)
Restructuring, integration and separation costs(9)(31)
Other expense (income), net(26)18 
Operating income740 444 
Interest income11 13 
Interest expense(396)(465)
Gain on extinguishment of debt— 178 
Foreign exchange and other(7)(30)
Income before income taxes$348 $140 
Six Months Ended June 30,
SalixInternationalSolta MedicalDiversifiedBausch + LombTotal
(in millions)202620252026202520262025202620252026202520262025
Revenues:
Total revenues$1,397$1,169$590$540$347$241$404$424$2,638$2,415$5,376$4,789
Less:
Cost of goods sold (a)
8782232219896357631,0091,004
Costs of other revenues——3531————13
Selling, general and administrative20522313011575608688915917
Research and development3238151217117710163
Segment profit$1,073$826$178$163$166$107$254$266$612$428$2,283$1,790
Corporate(521)(529)
Amortization of intangible assets(466)(512)
Goodwill impairments(1,426)— 
Restructuring, integration and separation costs(22)(32)
Other expense (income), net(58)3 
Operating (loss) income(210)720 
Interest income21 24 
Interest expense(798)(795)
(Loss) gain on extinguishment of debt(1)178 
Foreign exchange and other(18)(34)
(Loss) income before income taxes$(1,006)$93 
(a) Cost of goods sold excludes amortization and impairments of intangible assets.
During the six months ended June 30, 2026 and 2025, ten products represented 53% and 50% of total revenues, respectively.